Moreover, NfL can be relevant for therapeutic response monitoring: sNfL concentrations of MS patients treated with high efficacy therapies as Natalizumab or Fingolimod goes back to the level of healthy controls, significantly exceeding the amount of decrease in patients treated with platform therapies [50–52]. This evidence concerns the gene NEFL and myeloid sarcoma.